<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319680</url>
  </required_header>
  <id_info>
    <org_study_id>ABC-Treat</org_study_id>
    <nct_id>NCT03319680</nct_id>
  </id_info>
  <brief_title>Benefits of Hemodialysis With Citrate (ABC-treat) Study</brief_title>
  <acronym>ABC-treat</acronym>
  <official_title>Prospective Randomized Multicenter Study to Demonstrate the Benefits of Hemodialysis Without Acetate (With Citrate): ABC-treat Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Senefro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Senefro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized cross-over multicenter study to demonstrate the benefits of
      hemodialysis without acetate dialysate, with citrate.

      32 weeks duration, in two phases. In the first, half of the patients started with citrate
      dialysate for 16 weeks and the other half with acetate dialysate, and then patients cross.

      The primary objective is to analyze the effect of citrate dialysate on acid base balance
      decreasing chronic metabolic acidosis and avoiding / reducing post-dialytic alkalosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: to analyze the effect of citrate dialysate on acid base balance decreasing
      chronic metabolic acidosis and avoiding / reducing post-dialytic alkalosis.

      Secondary objectives:

        -  Evaluate the effect of dialysate on the variation of calcium pre and post-dialytic, as
           well as on the parathormone (PTH)

        -  Assess the effect of dialysate on inflammation

        -  Assess the effect of dialysate on the Elimination of small and medium-sized molecules

        -  Assess the effect of dialysate on the tolerance to the hemodialysis sessions

        -  Assess the effect of dialysate on nutritional parameters

      Patients: Adult patients dialysed three times per week for at least 3 months will be enrolled
      in 12 Spanish dialysis centres. Catheter as vascular access will be excluded.

      Design: prospective randomized multicenter, cross-over trial of chronic haemodialysis
      patients to compare the effect of citrate dialysate with acetate dialysate.

      Duration of study: 32 weeks, in two phases. Randomised to 16 weeks of hemodialysis with
      acetate followed by 16 weeks of citrate or 16 weeks of hemodialysis with citrate followed by
      16 weeks of acetate. Each patient will serve as control of itself and there will be no
      changes in the pattern of dialysis during the study with the exception of the dialysate,
      following the usual pattern of work
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of citrate dialysate on acid base status in hemodialysis patients measured by pH, BEecf and Bicarbonate at the end of HD session.</measure>
    <time_frame>32 weeks</time_frame>
    <description>The anion gap will be calculated as: Anion gap = [Na+] - ([Cl-] + [CO3H-])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of citrate dialysate with acetate dialysate on calcium level</measure>
    <time_frame>32 weeks</time_frame>
    <description>Calcium (mg/dl) blood determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of citrate dialysate with acetate dialysate on phosphate level</measure>
    <time_frame>32 weeks</time_frame>
    <description>Phosphate (mg/dl) blood determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of citrate dialysate with acetate dialysate on parathormone level.</measure>
    <time_frame>32 weeks</time_frame>
    <description>Parathormone (pg/ml) blood determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation status by blood determination of IL-6</measure>
    <time_frame>32 weeks</time_frame>
    <description>IL-6 (UI) blood determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation status by blood determination of us-PCR</measure>
    <time_frame>32 weeks</time_frame>
    <description>us-PCR (UI) blood determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation status by blood determination of ERI</measure>
    <time_frame>32 weeks</time_frame>
    <description>EPO Resistance Index (ERI) is calculated according to the following formula:
ERI = EPO Dose (U/kg/week) / Hb (g/dl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of citrate dialysate on the hemodialysis elimination of small and medium-sized in molecules using reduction ratio (RR) of Urea</measure>
    <time_frame>32 weeks</time_frame>
    <description>Urea reduction rates (RR) will be calculated as: RR (%) = [(Cpre - post)/Cpre] x 100.
Where Cpre and Cpost are the concentrations of pre and post dialysis analyzed substances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of citrate dialysate on the hemodialysis elimination of small and medium-sized in molecules using reduction ratio (RR) of Beta2-microglobulin</measure>
    <time_frame>32 weeks</time_frame>
    <description>β2m reduction rates (RR) will be calculated as: RR (%) = [(Cpre - post)/Cpre] x 100.
Where Cpre and Cpost are the concentrations of pre and post dialysis analyzed substances.
β2m concentrations at the end of the session will be corrected for concentration using a correction factor (FC) based on concentration of plasma proteins (PT): FC = PTpre/PTpost Where PTpre and PTpost are the concentrations of pre and post dialysis total proteins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of citrate dialysate on the tolerance to the hemodialysis sessions by determining number of intradyalitic hypotensions</measure>
    <time_frame>32 weeks</time_frame>
    <description>Compare the effect of citrate dialysate with acetate dialysate on reduction ratio (RR) of hypotensive episodes (clinical syntoms) during the hemodialysis sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of citrate dialysate on the nutritional parameters measured by biological parameters</measure>
    <time_frame>32 weeks</time_frame>
    <description>Weight (Kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of citrate dialysate on the nutritional parameters measured by biological parameters</measure>
    <time_frame>32 weeks</time_frame>
    <description>Normalized-protein catabolism rate corrected by body weight (PCR-n) is calculated using the following formula: PCRn = PCR/weight (kg) PCR= (9.35×G) + (0.00028×V) G: generation of interdialytic urea: G = [(C3-C2)×V]/2646 is the generation of interdialytic urea C2 = urea concentration at the end of hemodialysis C3 = urea concentration at the start of the following hemodialysis session parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hemodialysis-Induced Symptom</condition>
  <arm_group>
    <arm_group_label>Citrate dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodialysis with citrate dialysate during 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetate dialysate</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hemodialysis with acetate dialysate during 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Citrate dialysate</intervention_name>
    <description>Compare the effect of citrate dialysate with acetate dialysate</description>
    <arm_group_label>Citrate dialysate</arm_group_label>
    <other_name>Acetate dialysate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient conventional hemodialysis three times per week for at least three months.

          -  Arteriovenous fistula as vascular access

          -  Patients who have given their informed consent in writing.

        Exclusion Criteria:

          -  Catheter as vascular access

          -  Allergy or intolerance to citrate

          -  Patients with sufficient cognitive impairment that would prevent the compression of
             information and informed consent.

          -  Inflammatory intercurrent diseases (chronic infections, autoimmune diseases or tumors)
             that can mask the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Perez-Garcia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology department. Hospital universitario Infanta Leonor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia de Sequera, PhD</last_name>
    <phone>911918502</phone>
    <email>patricia.desequera@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Molina, PhD</last_name>
    <email>manuel.molina4@carm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Castellón</name>
      <address>
        <city>Castelló de la Plana</city>
        <state>Castellón</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramón Pons</last_name>
      <email>joserapons@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alba Segarra</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Pérez-Alba</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramón Pons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <state>Madrid</state>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Bueno</last_name>
      <email>blanca.bueno@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Jose Luis Merino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Domínguez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vicente Paraiso</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blanca Bueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Echarri</last_name>
      <email>rocio.echarri@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Yesica Amezquita</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Cirugeda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vicente Barrio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocío Echarri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gracia Alvarez</last_name>
      <email>alvarez.gracia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Molina</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gracia Álvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iñigo Moina</last_name>
      <email>INIGO.MOINAEGUREN@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Javier Arrieta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iñigo Moina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Usansolo</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Inés Muñoz</last_name>
      <email>ROSAINES.MUNOZGONZALEZ@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Isabel Martínez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa Inés Muñoz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel De Arriba</last_name>
      <email>garribad@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Sánchez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Angeles Basterrechea</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Alberto Blazquez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Alexandra Fiallos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Milena Villabon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel De Arriba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitary Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28030</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia de Sequera, PhD</last_name>
      <phone>0034911918592</phone>
      <email>patricia.desequera@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Patricia de Sequera, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Pérez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Mérida</last_name>
      <email>evameridaherrero@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Claudia Yuste</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Mérida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32205</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfoso Otero</last_name>
      <email>Alfonso.Otero.Gonzalez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Beatriz Ferreiro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Iglesias</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Jesús Camba</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Paz Borrajo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfoso Otero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocío Valverde</last_name>
      <email>rociovalor84@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Clotilde Ríos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocío Molas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocío Valverde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Gil</last_name>
      <email>luisgilsacaluga@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Amelia Dueñas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Aguilar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Gil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.senefro.org/</url>
    <description>Sponsor web page</description>
  </link>
  <reference>
    <citation>Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M. Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol. 2009 Mar 5;10:7. doi: 10.1186/1471-2369-10-7.</citation>
    <PMID>19265544</PMID>
  </reference>
  <reference>
    <citation>Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009 Sep;4(9):1459-64. doi: 10.2215/CJN.02590409. Epub 2009 Aug 6.</citation>
    <PMID>19661218</PMID>
  </reference>
  <reference>
    <citation>Bryland A, Wieslander A, Carlsson O, Hellmark T, Godaly G. Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. Diab Vasc Dis Res. 2012 Jan;9(1):42-51. doi: 10.1177/1479164111424297. Epub 2011 Nov 1.</citation>
    <PMID>22045866</PMID>
  </reference>
  <reference>
    <citation>Daimon S, Dan K, Kawano M. Comparison of acetate-free citrate hemodialysis and bicarbonate hemodialysis regarding the effect of intra-dialysis hypotension and post-dialysis malaise. Ther Apher Dial. 2011 Oct;15(5):460-5. doi: 10.1111/j.1744-9987.2011.00976.x.</citation>
    <PMID>21974699</PMID>
  </reference>
  <reference>
    <citation>Grundström G, Christensson A, Alquist M, Nilsson LG, Segelmark M. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol. 2013 Oct 9;14:216. doi: 10.1186/1471-2369-14-216.</citation>
    <PMID>24103587</PMID>
  </reference>
  <reference>
    <citation>Molina Nuñez M, de Alarcón R, Roca S, Álvarez G, Ros MS, Jimeno C, Bucalo L, Villegas I, García MÁ. Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective cross-over study. Blood Purif. 2015;39(1-3):181-7.</citation>
    <PMID>25791278</PMID>
  </reference>
  <reference>
    <citation>Kuragano T, Kida A, Furuta M, Yahiro M, Kitamura R, Otaki Y, Nonoguchi H, Matsumoto A, Nakanishi T. Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. Artif Organs. 2012 Mar;36(3):282-90. doi: 10.1111/j.1525-1594.2011.01349.x. Epub 2011 Sep 29. Erratum in: Artif Organs. 2013 Aug;37(8):746.</citation>
    <PMID>21954915</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

